The PSI and ETH Zurich Center for Radiopharmaceutical Sciences covers the full range of activities for the production and clinical testing of medicinal radiocompounds.
Scientific Highlights
Un incroyable succès
Araris Biotech AG, spin-off du PSI, obtient une valorisation au niveau «licorne»
IMPACT: pour la société suisse
Pour être à la pointe, au niveau mondial, dans le domaine des muons et de la production de radionucléides médicaux: l'importance de la mise à niveau prévue.
Dr. Chiara Favaretto has been honored with the Alavi-Mandell Award 2024
We congratulate Dr. Chiara Favaretto for the excellent research work she did during her time at the Center for Radiopharmaceutical Sciences.
The Executive Committee on Personalized Health and Related Technologies (PHRT) has supported the PROGNOSTIC translational Project with a Grant of CHF 2 million
The translational project "PROGNOSTICS", proposed by a consortium led by Prof. Roger Schibli, received CHF 2 million funding from the PHRT initiative of the ETH Domain(https://www.sfa-phrt.ch/two-clinical-trial-projects-launched-transforming-clinical-care-with-eth-technologies/). The study is being conducted with the Co-applicants Prof. Dr. med. Damian Wild at the University Hospital Basel and Prof. Dr. Nicola Aceto of the ETHZ. The consortium will test a new radiopharmaceutical developed at the Center for Radiopharmaceutical Sciences in 36 patients with advanced prostate cancer.